Labetalol
- Generic Name
- Labetalol
- Brand Names
- Trandate
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O3
- CAS Number
- 36894-69-6
- Unique Ingredient Identifier
- R5H8897N95
- Background
Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.
Labetalol was granted FDA approval on 1 August 1984.
- Indication
Labetalol injections are indicated to control blood pressure in severe hypertension. Labetalol tablets are indicated alone or in combination with antihypertensives like thiazides and loop diuretics to manage hypertension.
- Associated Conditions
- Chronic Stable Angina Pectoris, Hypertension, Hypertensive Emergency, Hypertensive crisis, Pheochromocytoma, Subarachnoid Hemorrhage
- Associated Therapies
- -
Comparison of Tab.Labetalol and Tab.Nifedipine for Management of Postpartum Hypertension
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- Dow University of Health Sciences
- Target Recruit Count
- 98
- Registration Number
- NCT02426177
Perfusion and Antihypertensive Therapy in Acute Ischemic Stroke
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 65
- Registration Number
- NCT02327793
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Oral Nifedipine Versus Oral Labetalol
- Conditions
- Interventions
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT02168309
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.
- Conditions
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- Dow University of Health Sciences
- Target Recruit Count
- 190
- Registration Number
- NCT02050529
- Locations
- 🇵🇰
Civil Hospital Karachi, Karachi, Sindh, Pakistan
Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- Gynuity Health Projects
- Target Recruit Count
- 894
- Registration Number
- NCT01912677
- Locations
- 🇮🇳
Daga Women's Hospital, Nagpur, Maharashtra, India
🇮🇳Government Medical College, Nagpur, Maharashtra, India
Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2013-05-17
- Lead Sponsor
- Saint Thomas Hospital, Panama
- Target Recruit Count
- 261
- Registration Number
- NCT01538875
- Locations
- 🇵🇦
Saint Thomas Maternity Hospital, Panama, Panama
Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol and Diltiazem
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2014-04-01
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 184
- Registration Number
- NCT01408524
Labetalol and Esmolol: Vital Signs and Post Operative Pain Management
- Conditions
- Interventions
- First Posted Date
- 2010-05-03
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 75
- Registration Number
- NCT01114971
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
Nicardipine Versus Labetalol During Intubation
- Conditions
- Interventions
- First Posted Date
- 2009-12-31
- Last Posted Date
- 2009-12-31
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT01041066
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department
- Conditions
- Interventions
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 226
- Registration Number
- NCT00765648
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Texas Health Science Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.